Mission: Affordable—GSK, Bharat Biotech Slash Malaria Shot Costs

As a significant stimulus for global health equity, Bharat Biotech and GlaxoSmithKline (GSK) have announced that they intend to reduce the price of the world's first malaria vaccine, RTS,S/AS01E, by more than half by 2028. This is as part of a long-term approach to promote sustainable and affordable access to the vaccine in areas where malaria is endemic, especially in sub-Saharan Africa.

 

Why It Matters

The Partnership

Pricing Outlook

Sources: GSK Press Release, Economic Times, UNICEF